ARQT Arcutis Biotherapeutics

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.

Details for the company’s participation are as follows:

        Fireside Chat Date: Tuesday, April 8, 2025

        Fireside Chat Time: 11:00 am EDT

The webcast for this conference may be accessed at the “” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit  or follow Arcutis on , , and .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Media

Amanda Sheldon, Head of Corporate Communications

Investors

Latha Vairavan, Vice President, Finance and Corporate Controller



EN
27/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcutis Biotherapeutics

 PRESS RELEASE

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatm...

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere on the body for any durationAbout 1.8 million children ages 2 to 5 with atopic dermatitis are topically treated in the U.S.Sixth FDA approval for ZORYVE in just over three yearsCommercial product expected to be available by the end of October 2025 WESTLAKE VILLAGE, Calif., Oct....

 PRESS RELEASE

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis’ common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October...

 PRESS RELEASE

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third ...

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET. In addition to discussing third quarter 2025 financial results, th...

 PRESS RELEASE

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at...

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin typesNew data show improved quality of life and decreased impact on families for investigational ZORYVE cream 0.05% in children aged 2–5 years with atopic dermatitisData demonstrate both ZORYVE cream 0.3% and ZORYVE foam 0.3% improved signs and symptoms of plaque psoriasis in individuals with facial and/or genital involvement WEST...

 PRESS RELEASE

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious...

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough Award”ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined—eczema, plaque psoriasis, and seborrheic dermatitisCream and leave-in foam options are uniquely formulated to be used anywhere on the body once per day and on diverse skin and hair typesZORYVE was shown to be safe and well-tolerated and ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch